Open Access Rheumatology-Research and Reviews最新文献

{"title":"Ophthalmic Posterior Segment OCTA Metrics as Potential Biomarkers for Systemic Involvement in Systemic Sclerosis, Systemic Lupus Erythematosus, and Behçet Disease: A Systematic Review.","authors":"Michael Drakopoulos, Hayden Flynn Sikora, Joseph D Fahey, Rukhsana G Mirza","doi":"10.2147/OARRR.S511810","DOIUrl":"https://doi.org/10.2147/OARRR.S511810","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the potential of quantitative ophthalmic posterior segment optical coherence tomography angiography (OCTA) imaging metrics to serve as biomarkers for systemic involvement in three rheumatologic diseases, systemic sclerosis (SSc), systemic lupus erythematosus (SLE), and Behçet disease (BD), by reviewing the reported correlations between such OCTA metrics and clinically relevant features of systemic involvement in these diseases.</p><p><strong>Methods: </strong>This review is a correlational study conducted through a systematic review of the PubMed database for articles reporting OCTA metrics in any of SSc, SLE, and BD. Articles correlating ophthalmic posterior segment OCTA metrics to clinically relevant features of systemic involvement, specifically serum, cerebrospinal fluid (CSF), or other established biomarkers; systemic symptom and severity scores; stage; non-ocular organ involvement; non-ocular imaging findings; and medication use were included.</p><p><strong>Results: </strong>OCTA parameters have been significantly correlated to autoantibody presence, digit and pulmonary involvement, disease stage, and medication use in SSc with significance values ranging from p = 0.008 to p = 0.048. OCTA parameters have been significantly correlated to serum markers, renal and cardiac involvement, damage indices, and medication use in SLE with significance values ranging from p < 0.0001 to p = 0.028. OCTA parameters have been correlated to systemic vascular involvement in BD with significance value p = 0.006.</p><p><strong>Conclusion: </strong>Ophthalmic posterior segment OCTA metrics may provide value in prognosis, stratification, and treatment monitoring of the examined rheumatologic conditions. These results warrant further study.</p>","PeriodicalId":45545,"journal":{"name":"Open Access Rheumatology-Research and Reviews","volume":"17 ","pages":"87-100"},"PeriodicalIF":1.7,"publicationDate":"2025-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12044345/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144019600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Biological Therapies on Quality of Life in Rheumatoid Arthritis: A Narrative Review.","authors":"Abdimutalib Mamasaidov, Kyazbek Sakibaev, Symbat Zhumabaeva, Ulanbek Isakov, Chynara Abdasbekovna Eshbaeva, Joldubai Abdyllaev, Bektur Abdikhalilov, Rana Sherbaevna Salieva","doi":"10.2147/OARRR.S523778","DOIUrl":"https://doi.org/10.2147/OARRR.S523778","url":null,"abstract":"<p><p>Rheumatoid arthritis (RA) is a chronic inflammatory disease that causes joint damage, pain, and disability, leading to significant impairments in patients' physical, mental, and social well-being. While biological disease-modifying antirheumatic drugs (bDMARDs) such as tumor necrosis factor (TNF) inhibitors, interleukin-6 (IL-6) inhibitors, and Janus kinase (JAK) inhibitors have revolutionized the treatment of RA by effectively controlling disease activity, their influence on patients' quality of life (QoL) is crucial but not fully understood. The aim of this review is to evaluate the impact of bDMARDs on QoL in RA patients, particularly focusing on domains such as physical functioning, pain, fatigue, mental health, and social participation. A comprehensive literature search was conducted in databases such as PubMed and the Cochrane Library, including randomized controlled trials, cohort studies, and surveys assessing QoL outcomes in RA patients receiving bDMARD therapy. The review includes studies that utilized the Health Assessment Questionnaire (HAQ), EuroQol-5 Dimension (EQ-5D), and Short Form-36 (SF-36), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Fatigue Severity Scale (FSS), and Patient Global Assessment (PtGA) QoL questionnaires, among others, to assess patient-reported outcomes. The findings of the current review suggest that bDMARDs significantly improve QoL in RA patients by reducing pain, fatigue, and disability while enhancing physical function and mental well-being. However, variability in patient responses, side effects, and the long-term impact of these therapies remain key concerns. Future studies with standardized QoL assessments and longer follow-up periods are needed to provide a more comprehensive understanding of the sustained effects of bDMARD therapy on RA patients' overall well-being.</p>","PeriodicalId":45545,"journal":{"name":"Open Access Rheumatology-Research and Reviews","volume":"17 ","pages":"73-86"},"PeriodicalIF":1.7,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12034252/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144045371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Severe COVID-19 in Patients with Immune-Mediated Rheumatic Disorders: A Case-Control Study.","authors":"Jamal Al-Saleh, Wafae Rachidi, Naureen Ali Khan, Mohammed G Ahmed, Hend Al-Saidi, Noura Zamani, Nasir Elamin Elhag Elsidig, Ahmed Abdelmoniem Negm, Faisal Elbadawi","doi":"10.2147/OARRR.S510631","DOIUrl":"https://doi.org/10.2147/OARRR.S510631","url":null,"abstract":"<p><strong>Purpose: </strong>To assess the impact of severe COVID-19 in patients with immune-mediated rheumatic diseases (im-RD) and compare their morbidity, mortality, hospitalization issues, post-COVID-19 sequelae, and the financial burden of COVID-19 with those of patients without im-RD.</p><p><strong>Patients and methods: </strong>We conducted a retrospective case-control study that included 132 consecutive patients with im-RD who visited the Rheumatology Department of a public hospital in the Emirate of Dubai and were hospitalized for COVID-19 infection between March 1st, 2020, and December 31st, 2021, (cases). We included 264 and 132 age- and sex-matched patients without im-RD in matched-I and matched-II control groups, respectively. The median age of patients and controls was 48.5 years, and 74.2% were female. Patients with im-RD were paired with an unforced nearest neighbor match using a caliper width of 0.2 standard deviations of the matched-II control group's propensity score. We compared the relative risk of death, disease progress, use of medical resources, and financial impact of COVID-19 between patients and controls.</p><p><strong>Results: </strong>Patients with im-RD had higher mortality rates than the matched-I (odds ratio, OR: 11.2, p < 0.000) and matched-II (OR: 16.8, p < 0.006) control groups. The overall complication rate was also significantly higher in patients with im-RD than in matched-I (OR = 2.9, p < 0.000) and matched-II (OR = 2.8, P < 0.0001) control groups. Lastly, patients with im-RD required more frequent visits to the clinic, a longer recovery time following hospital discharge, and increased healthcare costs compared to the control groups.</p><p><strong>Conclusion: </strong>COVID-19 infection in patients with im-RD is associated with increased morbidity and mortality, exerting a significant burden on the healthcare system.</p>","PeriodicalId":45545,"journal":{"name":"Open Access Rheumatology-Research and Reviews","volume":"17 ","pages":"57-72"},"PeriodicalIF":1.7,"publicationDate":"2025-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11986260/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144053449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Grip Strength Impairment and Neuropathic-Like Pain as Predictors of Functional Decline in Hand Osteoarthritis.","authors":"Sylvain Mathieu, Françoise Fayet, Marie-Hélène Salembien, Malory Rodere, Martin Soubrier, Anne Tournadre","doi":"10.2147/OARRR.S512888","DOIUrl":"10.2147/OARRR.S512888","url":null,"abstract":"<p><strong>Objective: </strong>(1) To define the factors associated with pain, functional limitation, grip strength (GS), sarcopenia and quality of life (QoL) in hand osteoarthritis (HOA) patients and (2) to compare the characteristics of HOA patients with or without neuropathic-like pain.</p><p><strong>Methods: </strong>The clinical parameters (numeric rating scale (NRS) for pain, Functional Index for HOA (FIHOA), GS, QoL, and sarcopenia) were completed by hand radiographs and biological analysis. A neuropathic-like pain was retained if the DN4 score was ≥4/10. We performed a cross-sectional study comparing the patients' characteristics using the Student's <i>t</i>-test or Chi-square. The relation between clinical parameters and others was studied with Spearman correlation or logistic regression.</p><p><strong>Results: </strong>110 hOA patients (mean age of 66.2 years and 89% of women) were included. Twenty-eight HOA patients presented a comorbidity (25.7%: 28/109) and eight had sarcopenia (8/63: 12.7%). Hand GS was negatively associated with age (r=-0.23; p=0.049), higher in men (p=0.003), and lower in erosive disease (p=0.03). Sarcopenia significantly correlated with higher pain intensity (p=0.046), greater functional impairment (FIHOA, p=0.01), and lower QoL (p=0.03). The presence of comorbidity altered the QoL (p=0.047). Depression was significantly associated with all clinical parameters, except GS. Sixty HOA patients had neuropathic-like pain (56.0%); these were younger, had a higher FIHOA, and reported more night awakening and morning stiffness; however, C-reactive protein (CRP) levels were not different.</p><p><strong>Conclusion: </strong>Neuropathic-like pain and sarcopenia exacerbate functional decline in HOA, highlighting the need for targeted interventions beyond conventional analgesics.</p>","PeriodicalId":45545,"journal":{"name":"Open Access Rheumatology-Research and Reviews","volume":"17 ","pages":"47-56"},"PeriodicalIF":1.7,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11977567/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143812356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Effectiveness of Intravenous Belimumab on Clinical Outcomes in Patients With Systemic Lupus Erythematosus in Saudi Arabia: The OBSErve Observational Study.","authors":"Ibrahim Abdulrazag Al-Homood, Ibrahim Almaghlouth, Alhussain Mohammed Asiri, Hanan Hamdy, Ali Alhammad, Alaa Mustafa, Mohamed Othman, Munther Khamashta, Tamer Elfishawy, Lindsey Teichman, Debora Dos Santos, Juliana Domenico Queiroz, Saeed Noibi","doi":"10.2147/OARRR.S497802","DOIUrl":"10.2147/OARRR.S497802","url":null,"abstract":"<p><strong>Purpose: </strong>To describe intravenous (IV) belimumab's clinical effectiveness in patients with systemic lupus erythematosus (SLE) in real-world practice in Saudi Arabia.</p><p><strong>Patients and methods: </strong>This retrospective, observational OBSErve study (GSK Study 215349) analyzed medical record data for adults with SLE receiving IV belimumab. Index date was the date of belimumab initiation. The primary endpoint was overall clinical response per physician judgement (categorized as worse, no improvement, improvement of <20%, 20-49%, 50-79%, ≥80%) at 6 months post-index. The secondary endpoints included changes from index in Safety of Estrogens in Lupus Erythematosus National Assessment-SLE Disease Activity Index (SELENA-SLEDAI) score and corticosteroid dose at 6 months post-index; and healthcare resource utilization (HCRU) 6 months pre- and post-index.</p><p><strong>Results: </strong>Of 47 patients enrolled, 44 patients completed ≥6 months of IV belimumab treatment and were included in the analysis. Most patients were female (91.5%) and the mean (standard deviation [SD]) age was 33.1 (8.1) years. At 6 months post-index, overall physician-assessed clinical improvements of ≥20% and ≥50% were reported for 97.7% (n=43) and 79.5% (n=35) of patients, respectively; 2.3% (n=1) of patients had no improvement, and no patient worsened. Mean SELENA-SLEDAI score decreased by 7.8 points during the 6 months post-index. Mean (SD) corticosteroid dose decreased from 10.2 (7.5) mg/day at index to 6.2 (3.4) mg/day at 6 months post-index. Reductions in unscheduled physician office and emergency room visits were observed during the post-index versus pre-index periods.</p><p><strong>Conclusion: </strong>Real-world data from patients with SLE treated with IV belimumab in Saudi Arabia demonstrated clinical improvements and reductions in corticosteroid dose and HCRU. Although the low number of patients and lack of a control group limit interpretation, the similar findings to the other OBSErve studies support the effectiveness of belimumab for patients with SLE in Saudi Arabia.</p>","PeriodicalId":45545,"journal":{"name":"Open Access Rheumatology-Research and Reviews","volume":"17 ","pages":"33-45"},"PeriodicalIF":1.7,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11835778/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143460028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of Positron Emission Tomography-Computed Tomography Scan in Reaching Definite Diagnosis in Patients With Fever of Unknown Origin and Inflammation of Unknown Origin in Rheumatology Outpatient Clinic.","authors":"Umut Yılmaz Koreli, Ege Sinan Torun, Mine Adaş","doi":"10.2147/OARRR.S499694","DOIUrl":"10.2147/OARRR.S499694","url":null,"abstract":"<p><strong>Introduction: </strong>Patients with fever of unknown origin (FUO) and/or inflammation of unknown origin (IUO) challenge clinicians in daily rheumatology practice. Positron emission tomography-computed tomography (PET/CT) is being used in the diagnostic workup of patients with FUO and/or IUO. This study aims to evaluate the clinical utility and diagnostic performance of PET/CT in the rheumatology outpatient clinic among FUO and IUO patients.</p><p><strong>Methods: </strong>Patients admitted to Prof. Dr. Cemil Taşcıoğlu City Hospital Internal Medicine Rheumatology Outpatient Clinic between February 2022 and September 2023 with FUO and/or IUO and for whom PET/CT scan was performed were included. Initial acute phase reactants, PET/CT results, definite diagnosis and follow-up of patients without a definite diagnosis were retrospectively evaluated.</p><p><strong>Results: </strong>Thirty patients were included. Fifteen patients received a final diagnosis. Diagnoses were ankylosing spondylitis (n=4), rheumatoid arthritis (n=1), systemic lupus erythematosus (n=3), giant cell arteritis (n=1), adult onset Still disease (n=1), undifferentiated connective tissue disease (n=1), undifferentiated vasculitis (n=1) and crystal arthropathy (n=1), Hodgkin lymphoma (n=1) and cryptococcosis (n=1). PET/CT's diagnostic accuracy was 66.7%, sensitivity was 100% but specificity was 33%. In 15 patients a definite diagnosis was not reached but in most of these patients, fever did not recur and acute phase reactants regressed either spontaneously or with empiric treatment.</p><p><strong>Discussion: </strong>PET/CT reliably helps 50% FUO/IUO patients in receiving definite diagnosis. PET/CT's high sensitivity implies that negative results can reliably exclude malignancies in most cases. However, due to its low specificity, positive test may not always imply a serious underlying condition. Majority of the definite diagnoses were rheumatic diseases with a very low proportion of infections and malignancies. This is mainly due to the detailed initial evaluations that are performed in internal medicine clinics. Future studies with more patients will better define the role of PET/CT in FUO/IUO patients in rheumatology clinics.</p>","PeriodicalId":45545,"journal":{"name":"Open Access Rheumatology-Research and Reviews","volume":"17 ","pages":"25-32"},"PeriodicalIF":1.7,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11807778/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143392229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute Clinical Features and Persistence of Joint Pain in Probable Cases of Chikungunya Fever in Eritrea.","authors":"Okbu Frezgi, Araia Berhane, Ghide Ghebrewelde, Henok Tekie, Tsegezab Kiflezgi, Abdelaziz Mohamedsied, Yonas Tekie, Medhanie Medhin Asrat, Tewaldemedhine Gebrejesus","doi":"10.2147/OARRR.S465082","DOIUrl":"10.2147/OARRR.S465082","url":null,"abstract":"<p><strong>Background: </strong>Chikungunya fever is a mosquito-borne viral illness that has re-emerged as an important global concern. Persistent arthralgia following chikungunya fever is common and requires advanced pharmacological interventions as pain does not respond well to analgesics.</p><p><strong>Objective: </strong>The study aimed to describe the acute clinical features of probable cases of chikungunya fever and risk factors associated with the persistence of joint pain.</p><p><strong>Methods: </strong>A prospective, descriptive cohort study was conducted on probable cases of chikungunya fever from October 2018 to March 2019 in the Tesseney subzone of Eritrea.</p><p><strong>Results: </strong>A total of 203 probable cases of chikungunya fever were enrolled, majority being males (68%) with a mean age of 39.2 years. The acute phase symptoms include the triad of polyarthralgia (97%), fever (96.1%), and skin rash (56.7%). Commonly affected joint sites were the wrist (59.4%) and interphalangeal joints of the hands (56.9%). Fever had a mean duration of 4.1 ± 3 days, while headache had a mean duration of 3.8 ± 3 days. Skin rash was maculopapular, which was pruritic in (85.2%) and the common involved sites were the hands (71%) and trunk (46.5%). Complete blood count during acute phase includes lymphocytosis (64.5%) and granulocytopenia (43.3%). Joint pain persisted at three months in 52.1% of cases and at six months in 21.7%. Age >41 (p = 0.001, OR: 1.588; 95% CI: 0.935-2.695) and having the O-type blood group (p = 0.033, OR: 0.704; 95% CI: 0.448-1.105) were found to be associated with the persistence of joint pain.</p><p><strong>Conclusion: </strong>Our study indicates polyarthralgia, fever, and skin rash as a triad of symptoms during the acute phase. Persistent arthralgia was a frequent long-term complication of chikungunya fever in which increasing age was identified to be a significant risk factor.</p>","PeriodicalId":45545,"journal":{"name":"Open Access Rheumatology-Research and Reviews","volume":"17 ","pages":"13-24"},"PeriodicalIF":1.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11796447/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143257008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Health Disparities in Rheumatology in the United States.","authors":"Grace C Wright, Patrick M Zueger, Catherine Copley-Merriman, Shahnaz Khan, Jessica Costello, Alisha Krumbach, Priya Reddy, Oishi Tanjinatus, Alvin F Wells","doi":"10.2147/OARRR.S493457","DOIUrl":"10.2147/OARRR.S493457","url":null,"abstract":"<p><strong>Objective: </strong>Underserved populations are often at risk of experiencing systematic healthcare disparities. Existing disparities in care access, quality of care received, and treatment outcomes among patients with rheumatic disease are not well understood.</p><p><strong>Methods: </strong>We conducted a targeted literature review to understand disparities in health outcomes, treatment patterns, and healthcare management faced by rheumatology patients in the United States, with a focus on rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS).</p><p><strong>Results: </strong>The findings of this review indicate that disparities in RA, PsA, and AS affect several historically underserved populations, including underrepresented racial and ethnic groups, persons with lower socioeconomic status (SES), persons experiencing homelessness, and patients with Medicare or Medicaid insurance types. The disparities experienced by these populations include greater disease activity and severity, decreased or delayed access to specialist care, decreased likelihood of receiving advanced therapeutics, and worse clinical outcomes.</p><p><strong>Conclusion: </strong>To provide equitable healthcare for all patients with RA, PsA, and AS, multiple closely linked health disparities must be addressed. Possible solutions include partnerships between healthcare systems and community-based organizations, targeted outreach tailored to patients with low SES, interventions to improve patient adherence and knowledge, and interventions to improve access to care for rural-residing and unhoused patients. In all, the findings of this literature review underscore the need for mitigation of health disparities in rheumatology care and may serve as a foundation for developing strategies to reduce disparities.</p>","PeriodicalId":45545,"journal":{"name":"Open Access Rheumatology-Research and Reviews","volume":"17 ","pages":"1-12"},"PeriodicalIF":1.7,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11727327/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142985138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of One Shot of Hyaluronic Acid in Hip Osteoarthritis: Postmarketing Clinical Follow-Up for Real-World Evidence.","authors":"Amparo Santamaría Torroba, María Pilar Acin Lazaro, Elena Gómez-Rubio, Pilar Coronel Granado","doi":"10.2147/OARRR.S485295","DOIUrl":"10.2147/OARRR.S485295","url":null,"abstract":"<p><strong>Purpose: </strong>This study aims to evaluate the real-world efficacy and safety of intra-articular (IA) hyaluronic acid (HA) injections in patients with hip osteoarthritis (OA). Given the increasing burden of hip osteoarthritis and limited evidence supporting viscosupplementation in this context, this research aims to provide valuable insights under real clinical practice conditions.</p><p><strong>Patients and methods: </strong>An observational, cross-sectional and retrospective study was conducted in a cohort of patients with hip OA treated with a single injection of HA (Adant One, Meiji Pharma Spain, Spain) from January 2021 to December 2022. Data on patient demographics, clinical characteristics, and treatment outcomes were collected. Efficacy regarding pain relief and/or function improvement was assessed at 6 months using the Visual Analogue Scale (VAS) and the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Data were pseudonymized. The study was approved by the Research Ethics Committee of the Autonomous Community of Aragon (CEICA).</p><p><strong>Results: </strong>The study included 40 patients with a mean age of 62.8 years, with 72.5% being female. Significant improvement was observed six-months post-treatment: 25% and 18.5% reduction in pain (VAS and WOMAC, respectively), 11.6% improvement in function (WOMAC), 7.4% improvement in stiffness (WOMAC), and 13.6% improvement in total WOMAC. No adverse events were reported.</p><p><strong>Conclusion: </strong>A single injection of IA HA significantly improved pain and function in patients with hip OA. These findings support the use of viscosupplementation for hip OA management and underscore the need for further studies to confirm these results and assess the long-term benefits of IA HA in hip OA.</p>","PeriodicalId":45545,"journal":{"name":"Open Access Rheumatology-Research and Reviews","volume":"16 ","pages":"157-163"},"PeriodicalIF":1.7,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11645952/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142830237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of Hyperuricemia and Rheumatoid Factor Positivity Among Patients Aged 35 and Above in Huye District, Southern Province of Rwanda.","authors":"Ruth Umukundwa, Elyse Akimana, Vedaste Nsanzimana, Herbert Tendayi Mapira, Cuthbert Musarurwa","doi":"10.2147/OARRR.S495467","DOIUrl":"https://doi.org/10.2147/OARRR.S495467","url":null,"abstract":"<p><strong>Background: </strong>Hyperuricemia, a precursor to gout, and rheumatoid factor positivity (RF), an autoantibody linked to rheumatoid arthritis (RA), but also present in various conditions and healthy adults, hold significant health implications, including potential links to cardiovascular diseases and metabolic risks. In Rwanda, data on these conditions in individuals aged 35 and above are lacking. This study aimed to determine the prevalence of hyperuricemia and RF positivity in patients aged 35 and above in Huye district of Rwanda.</p><p><strong>Patients and methods: </strong>We conducted a cross-sectional study from October 2023 to January 2024, enrolling 367 patients from Huye and Matyazo Health Centers. We measured rheumatoid factor (RF), C-reactive protein (CRP), and serum uric acid levels, and evaluated risk factors using structured questionnaires.</p><p><strong>Results: </strong>Among the patients, 38.1% had hyperuricemia, with 9.8% RF positivity and 3.3% CRP positivity. Hyperuricemia was more prevalent in older patients (p = 0.045) and females (p = 0.001). Notably, 12% of hyperuricemic patients had positive RF results.</p><p><strong>Conclusion: </strong>This study reveals high hyperuricemia rates and low RF/CRP positivity in patients aged 35 and above, with women and older individuals being more affected. The co-occurrence of hyperuricemia and RF has significant health impacts, highlighting the need for further research on metabolic disorders linked to hyperuricemia to inform better interventions. Our findings underscore the importance of addressing the conditions associated with these abnormalities to improve health outcomes in Rwanda's aging population.</p>","PeriodicalId":45545,"journal":{"name":"Open Access Rheumatology-Research and Reviews","volume":"16 ","pages":"147-156"},"PeriodicalIF":1.7,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11608041/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142773566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}